Market Overview

NovaBay Pharmaceuticals Launches Avenova® Direct on


Original formulation of Avenova® for the management
of bacterial dry eye is now available at an affordable price without a

Pharmaceuticals, Inc.
(NYSE:NBY), a biopharmaceutical
company focusing on commercializing Avenova®
for the domestic eye care market, announces that Avenova®
Direct is available at affordable pricing and without a prescription on
through the Company's new direct-to-consumer online channel. Avenova,
the leading lid and lash spray, is designed for the removal of bacteria
and debris on and around the eyelid margin that contribute to bacterial
eye infections, which represent approximately 85% of the dry eye market.
The Avenova Direct page on is available here.

"Patients throughout the U.S. can now purchase Avenova Direct without a
prescription in Avenova's original prescription formulation," said
Justin Hall, Interim President and CEO of NovaBay. "For many years, the
bacterial microorganisms that are the underlying cause of the vast
majority of dry eye cases were almost impossible to manage. Avenova
Direct effectively manages bacterial dry eye through our pure 0.1%
hypochlorous acid formulation in saline, which is free from bleach,
surfactants and other impurities. I firmly believe this is the best
product available for the topical treatment of these chronic ocular
bacterial infections.

"While prescription Avenova continues to be available through retail
pharmacies and direct in-office sales by certain eye care specialists,
patients and physicians have asked for greater accessibility to the
product. In response, we are launching our new U.S. direct-to-consumer
channel, which is a significant step in ensuring easy access at an
affordable price," he added. "This direct channel further provides
NovaBay with set pricing that is not impacted by the current health plan
reimbursement environment."

Avenova Direct is available from Amazon in the U.S. in a 20ml size for
$29.99. Avenova is gentle, refreshing and soothing for everyday eyelid
and eyelash use.

The launch of NovaBay's direct-to-consumer channel is supported by
Avenova's existing brand awareness campaign. In addition, the Company is
conducting a comprehensive online promotional strategy that includes
search engine optimization, Google Ads and Amazon promotions using
searchable keywords, Facebook lead ads and social media marketing
targeting influencers, and email campaigns focused on ophthalmologists,
optometrists and current and former Avenova patients.

About Avenova®

Avenova is an eye care product formulated with our proprietary, stable
and pure form of hypochlorous acid. Avenova is designed for removal of
the microorganisms and debris that contribute to conditions such as
meibomian gland dysfunction, dry eye and blepharitis. Avenova is
marketed to optometrists and ophthalmologists throughout the U.S. by
NovaBay's direct salesforce and available online through

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on
commercializing and developing its non-antibiotic anti-infective
products to address the unmet therapeutic needs of the global, topical
anti-infective market with its two distinct product categories: the
NEUTROX® family of products and the AGANOCIDE®
compounds. The Neutrox family of products includes AVENOVA®
for the eye care market, NEUTROPHASE® for wound care market,
and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target applications
in the dermatology and urology markets.

Forward-Looking Statements

This release contains forward-looking statements that are based upon
management's current expectations, assumptions, estimates, projections
and beliefs. These statements include, but are not limited to,
statements regarding our future listing on the NYSE, our ability to
continue as a going concern, and generally the company's expected future
financial results. These statements involve known and unknown risks,
uncertainties and other factors that may cause actual results or
achievements to be materially different and adverse from those expressed
in or implied by the forward-looking statements. Factors that might
cause or contribute to such differences include, but are not limited to,
risks and uncertainties relating to our ability to remain a publicly
listed company, maintain the support of our majority shareholders, and
ability to adhere to our approved NYSE compliance plan. Other risks
relating to NovaBay's business, including risks that could cause results
to differ materially from those projected in the forward-looking
statements in this press release, are detailed in NovaBay's latest Form
10-Q/K filings with the Securities and Exchange Commission, especially
under the heading "Risk Factors." The forward-looking statements in this
release speak only as of this date, and NovaBay disclaims any intent or
obligation to revise or update publicly any forward-looking statement
except as required by law.

Socialize and Stay informed on NovaBay's

Like us on Facebook
us on 
with NovaBay on 

Avenova Purchasing Information
NovaBay Avenova purchasing information:
Please call 800-890-0329 or

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at